Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Medication Adjustment Clear all
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1)

NCT03740737
View directory record Official record
Conditions
Infertility
Interventions
Follitropin delta, Placebo
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 34 Years · Female only
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Tempe, Arizona • Encino, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

NCT00765661
View directory record Official record
Conditions
Kidney Failure, Renal Failure
Interventions
Tacrolimus (Tacro™), Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Exenatide in Patients With Diabetic Neuropathy

NCT00855439
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
Interventions
Exenatide, Glargine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

NCT01561937
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
warfarin, eptacog alfa (activated), placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Sep 18, 2026, 5:16 AM EDT
Enrolling by invitation Phase 2 Interventional

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

NCT04093570
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Interventions
ASTX727
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Fountain Valley, California • Plantation, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study in Patients With Solid Tumors

NCT01215916
View directory record Official record
Conditions
Solid Tumors
Interventions
LY573636, Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Evaluating a New Way to Prepare Parents of Hospitalized Children for Discharge and Management of Child at Home

NCT01565785
View directory record Official record
Conditions
Patient Discharge
Interventions
The FSM-DPI.
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Steroid Free Immunosuppression in Liver Transplantation

NCT00296244
View directory record Official record
Conditions
Liver Cirrhosis, Liver Transplant Disorder
Interventions
Steroids, Basiliximab, Tacrolimus, Enteric-coated Mycophenolic acid (EC-MPA)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 72 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Sep 18, 2026, 5:16 AM EDT
Active, not recruiting Phase 2 Interventional

Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

NCT04517799
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Epidiolex, placebo oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 14 Years · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

NCT00482846
View directory record Official record
Conditions
Mucositis, Multiple Myeloma
Interventions
Palifermin, melphalan, questionnaire administration, autologous peripheral blood stem cell transplantation, quality-of-life assessment
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Sep 18, 2026, 5:16 AM EDT
Terminated Phase 1 Interventional

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

NCT03530683
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
Interventions
Maplirpacept (PF-07901801), Azacitidine, Venetoclax, Carfilzomib, Dexamethasone, Anti-CD20 Targeting agent, Isatuximab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
62
States / cities
Los Angeles, California • Pasadena, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 18, 2026, 5:16 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

NCT01256489
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Corneal Blindness
Interventions
Infliximab
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Stem Cell Transplantation for Sickle Cell Anemia

NCT01877837
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, Fludarabine, Melphalan, Stem Cells
Drug · Procedure
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
2 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive

NCT00264537
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo injections, Placebo capsules, Methotrexate capsules, Golimumab 50 mg injections, Golimumab 100 mg injections
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Mobile, Alabama • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Intra-arterial Chemotherapy for Spinal Metastases

NCT01637766
View directory record Official record
Conditions
Spinal Diseases, Spinal Metastases, Spinal Tumors
Interventions
Melphalan (intra-arterial infusion)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Vilazodone for Treatment of Geriatric Depression

NCT01608295
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vilazodone; Viibryd, Paroxetine; Paxil
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
60 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

NCT01476475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 18, 2026, 5:16 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

NCT06331312
View directory record Official record
Conditions
Polymyalgia Rheumatica
Interventions
Secukinumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 100 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Avondale, Arizona • Peoria, Arizona • Westlake Village, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

NCT01819129
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspart, Insulin aspart, Insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
77
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Sep 18, 2026, 5:16 AM EDT
Not listed Not applicable Interventional

Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure *On Hold Due to Global Pandemic*

NCT04226157
View directory record Official record
Conditions
Ischemic Stroke, Hypertension
Interventions
Home Blood Pressure Monitoring Device (Qardio Arm), Primary Care Provider Blood Pressure Management
Device · Other
Lead sponsor
MedStar Georgetown University Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Sep 18, 2026, 5:16 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Ketamine on Postoperative Clinical Outcomes

NCT01365195
View directory record Official record
Conditions
Colorectal Surgery
Interventions
Placebo, Ketamine high-dose, Ketamine low-dose
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 18, 2026, 5:16 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NCT01701219
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 18, 2026, 5:16 AM EDT
Withdrawn Early Phase 1 Interventional

Androgen Regulation of Priapism in Sickle Cell Disease

NCT01940718
View directory record Official record
Conditions
Priapism, Sickle Cell Disease, Hypogonadism
Interventions
Transdermal Androgel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 18, 2026, 5:16 AM EDT